welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
The U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). This approval represents the first drug approved for the treatment of thyroid eye disease.
The approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non-surgical treatment option,” said Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research.
Tepezza was approved based on the results of two studies (Study 1 and 2) consisting of a total of 170 patients with active thyroid eye disease who were randomized to either receive Tepezza or a placebo.
More from Teprotumumab News:
More from Teprotumumab Research:
(Author: Raymond S. Douglas)
Enfermedad Ocular Tiroidea¿Qué es la Enfermedad Ocular Tiroidea?...
Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 StudyResults from the phase 3 OPTIC study sho...
Comparison of Two Different Regimens of Intravenous Methylprednisolone for Patients With Moderate to Severe and Acti...The intravenous methylprednisolone (iv M...
Radiotherapy for Active Thyroid Eye DiseasePurpose: To critically review the publi...
Eyes on Graves’: LaQuilla’s Storyhttps://www.youtube.com/watch?v=98tJEN1C...
Catherine J. Hwang, MDDr. Catherine J. Hwang was born in New Y...
Advances in the Pharmacological Treatment of Graves’ OrbitopathyGraves' orbitopathy has a deteriorating ...